Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| ADVL1513 | COG | A Phase 1 Study of Entinostat; An Oral Histone Deacetylase Inhibitor; In Pediatric Patients with Recurrent or Refractory Solid Tumors; Including CNS Tumors and Lymphoma | Pediatric CIRB | Completed | |
| ADVL1514 | COG | A Phase 1 Study of ABI-009 (nab-Rapamycin) (IND# 133537) in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan | Pediatric CIRB | Available to Open | |
| ADVL1515 | COG | A Phase 1 Study of LY2606368, (prexasertib mesylate monohydrate) (IND# 132233), a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors | Pediatric CIRB | Completed | |
| ADVL1521 | COG | A Phase 2 Study of the MEK inhibitor Trametinib (IND #119346, NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia | Pediatric CIRB | Available to Open | |
| ADVL1522 | COG | A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; IND# 126953; NSC# 783609) in Children with Relapsed or Refractory Wilms Tumor; Rhabdomyosarcoma; Neuroblastoma; Pleuropulmonary Blastoma; Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma | Pediatric CIRB | Completed | |
| ADVL1614 | COG | A Phase 1/2 Study of VX15/2503 (IND #136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors | Pediatric CIRB | Available to Open | |
| ADVL1615 | COG | A Phase 1 Study of Pevonedistat (MLN4924, IND # 136078), A NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors | Pediatric CIRB | Available to Open | |
| ADVL1622 | COG | Phase 2 Trial of XL184 (Cabozantinib); an Oral Small-Molecule Inhibitor of Multiple Kinases; in Children and Young Adults with Refractory Sarcomas; Wilms Tumor; and Other Rare Tumors | Pediatric CIRB | Available to Open | |
| ADVL1712 | COG | A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924, IND#142772) Given in Combination with Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Pediatric CIRB | Available to Open | |
| ADVL1823 | COG | Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias | Pediatric CIRB | Available to Open |